The biological quality of physical plans, therefore, depends strongly on the prioritization of the DV constraints, Dr. Diot says, which rely on the planner, the technique used and the patient anatomy, while the biological quality of biologically-optimized plans depend only on the functional-structure selected for each organ.

"We also found that despite the advanced features and sophistication of the Monaco treatment planning system, it can be successfully implemented in a clinical environment without increasing workload," Dr. Miften reports.


*Biological-based optimization and volumetric modulated arc therapy delivery for stereotactic body radiation therapy. Med. Phys. 39(1), January 2012.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.

CONTACT: Stina Thorman, Vice President Corporate Communications, Elekta AB, +46 8 587 254 37, stina.thorman@elekta.com, Time zone: CET: Central European Time, or Michelle Lee Joiner, Director, Global Public Relations and Brand Management, Elekta, +1-770-670-2447, michelle.joiner@elekta.com, Time zone: ET: Eastern Time

Back to HCB News

More HCB News